Table 5 Risk factor analysis for PE occurrence within 1 year after lung cancer diagnosis
| Â | Â | Univariate | Multivariate** | ||
|---|---|---|---|---|---|
| Â | Â | sHR (95% CI) | p-value | sHR (95% CI) | p-value |
Age | <  55 | – | – | – | – |
55–65 | 0.82 (0.45–1.48) | 0.503 | 0.88 (0.48–1.60) | 0.665 | |
65–75 | 0.75 (0.40–1.37) | 0.346 | 0.91 (0.49–1.70) | 0.774 | |
≥ 75 | 0.72 (0.39–1.33) | 0.294 | 1.08 (0.56–2.08) | 0.828 | |
Gender | Male | – | – | – | – |
Female | 1.63 (1.08–2.47) | 0.020 | 1.68 (1.11–2.54) | 0.014 | |
Metastasis |  | 3.46 (2.18–5.50) | < 0.0001 | 2.51 (1.48–4.26) | 0.0006 |
VTE concomitant with cancer diagnosis* |  | 3.33 (0.80–13.97) | 0.100 |  |  |
Lung cancer surgery |  | 0.78 (0.41–1.50) | 0.456 |  |  |
Other surgery |  | 1.64 (0.98–2.75) | 0.061 |  |  |
Chemotherapy |  | 3.97 (2.58–6.09) | < 0.0001 | 3.13 (1.88–5.20) | < 0.0001 |
Bevacizumab |  | 1.39 (0.44–4.42) | 0.577 |  |  |
Oral targeted therapy |  | 2.38 (1.02–5.53) | 0.045 |  |  |
Radiotherapy |  | 2.10 (1.29–3.43) | 0.003 |  |  |
Blood transfusion |  | 1.53 (0.70–3.34) | 0.286 |  |  |
Non-surgical hospitalization |  | 1.74 (1.14–2.65) | 0.011 |  |  |